ESR1 and neoplasm: However, these results must be interpreted with caution, since ER+ BCs have been divided into luminal A and luminal B tumors in recent decades, where the latter were associated with higher sTIL levels, a higher tumor mutational burden (TMB), and a worse clinical outcome than the luminal A subgroup [35].